The North America tulathromycin market size was valued at USD 362 million in 2025 and is projected to grow from USD 389 million in 2026 to reach USD 705.75 million by 2034, growing at a CAGR of 7.7% during the forecast period 2026–2034.
The high prevalence of BRD and SRD drives the North American tulathromycin market. The North American entry of generic tulathromycin acts as a restraint on this market. On the other hand, a lucrative opportunity for new entrants in generic tulathromycin is an opportunity for the tulathromycin market.
Download a Free Sample To learn more about this report,
High Prevalence of Brd and Srd
BRD is the most common pathology in young and adult animals, affecting 20–25% of calves annually, 10% of which experience growth retardation and up to 6% die. Swine can also have an SRD prevalence rate of around 20%, with a mortality rate of up to 20% and a risk of sequelae in up to 40% of affected animals. Beyond the effects on animal health, BRD and SRD have a significant financial impact on the farmer because of the reduction in animal growth, the expense of diagnosis and treatment, mortality, and the cost of additional work.
Entry of Generic Tulathromycin
Two generic tulathromycin injectable medicines have just received FDA approval in 2021 for the treatment and management of specific diseases in both cattle and swine. Bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis is treated with the generic drugs Macrosyn and Increxxa in beef and non-lactating dairy cattle, suckling calves, dairy calves, and veal calves. Additionally, it's used to treat swine respiratory disease (SRD), which is a condition that affects swine and is brought on by pathogens like Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae.
The approved brand-name drug product Draxxin, first approved in 2005, shares the same active component (tulathromycin) with Macrosyn and Increxxa in the same dose form and concentration. These two generic medications are anticipated to reduce the demand for tulathromycin in the next few years. By consuming some of the demand for the name-brand Draxxin, the demand for generic medicines will increase more quickly.
Lucrative Opportunity for New Entrants in Generic Tulathromycin
The formulation of Draxxin, which contains the active component tulathromycin, is protected by patents in the United States, Canada, and other important markets. The patent in the United States, Canada, and Australia expires in February 2021. Till 2023, the active component tulathromycin is protected in Japan. Products containing generic tulathromycin are sold in a few nations, including Colombia, Vietnam, Belarus, Russia, Poland, and Croatia. Marketing permits for products containing generic tulathromycin.
This provides the participants with a lucrative opportunity to enter the industry and take advantage of the growth opportunity, particularly in the United States and Europe. Due to the high end-user spending power and greater reliance on beef and dairy cattle, the U.S. and Europe are the two largest markets for the consumption of antibiotics for BRD and SRD. During the forecast period, we anticipate the arrival of numerous new players in the tulathromycin market in these two areas.
Cattle represent a prominent segment of the North America tulathromycin market because the medicine is commonly prescribed by veterinarians to manage susceptible bacterial respiratory infections in beef and dairy herds. Demand is supported by the economic importance of cattle farming, the need to protect herd health, and efforts to reduce production losses associated with respiratory disease. Tulathromycin’s long-acting characteristics can support practical treatment protocols, particularly in large herds. Veterinary oversight, accurate diagnosis, responsible dosing, withdrawal-period compliance, and antimicrobial stewardship remain central to its appropriate use.
The swine segment is supported by the need to manage susceptible respiratory infections that can affect animal welfare, growth, and farm productivity. Tulathromycin may be incorporated into veterinarian-directed treatment programs after considering clinical symptoms, disease history, diagnostic results, and applicable product labeling. Demand is influenced by commercial pig production, herd density, biosecurity practices, and access to veterinary services. At the same time, producers are placing greater emphasis on vaccination, sanitation, ventilation, surveillance, and responsible antimicrobial use to prevent disease and limit unnecessary treatment.
Request Customizationto receive a tailored report.
Speak to an Analystto discuss market opportunities.
The U.S. dominates the country market and is expected to grow at a CAGR of 4.2% during the forecast period. The biggest market for tulathromycin is North America. The region controls much of the market despite only containing 5% of the world's population. The United States holds a monopolistic position in regional and international markets. The number of cattle in the United States is above 94.4 million, somewhat fewer than in 2019. More than 98% of all beef cattle kept in feedlots have been found to contract the virus, and more than 45% of all feedlot fatalities are attributable to bovine respiratory disease. Accordingly, farmers are taking extra precautions to prevent the anticipated events and administering tulathromycin for the disease's prevention and treatment. The number of swine in the United States has significantly increased recently. It has grown to 6 million as of 2020 and is likely to grow more. The U.S. FDA recently approved Macrosyn and Increxxa, two generic tulathromycin medications. These medications are anticipated to have a positive CAGR in the years to come for branded tulathromycin medications.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Severity: Notice
Message: Undefined variable: relatedReports
Filename: reportpages/rd.php
Line Number: 640
Backtrace:
File: /var/www/html/application/views/frontend/reportpages/rd.php Line: 640 Function: _error_handler
File: /var/www/html/application/controllers/FrontendRegionalReportController.php Line: 108 Function: view
File: /var/www/html/index.php Line: 364 Function: require_once
We are featured on:
sales@straitsresearch.com